Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $43.33
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have updated their coverage on the stock […]
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have updated their coverage on the stock […]
